Printer Friendly

American Bio Medica is Granted U.S. Patent; Intellectual Property Portfolio Continues to Expand.

KINDERHOOK, N.Y. -- American Bio Medica Corporation (NASDAQ:ABMC) announced today that they have been granted another patent from the United States Patent and Trademark Office related to the Company's Rapid Drug Screen(R) product. Patent Number 6,915,919 covers a container closure cap with a self-sealing slot. This self-sealing closure cap prevents leakage of the urine specimen through the slot after the Rapid Drug Screen test card has been removed.

With this grant, ABMC's intellectual property portfolio for its drug of abuse testing line increases to 9 United States patents and 15 foreign patents, in addition to a number of pending patent applications both within the US and internationally.

For more information on ABMC or its drug testing products, please visit

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen, Rapid One(R), Rapid TEC(R), RDS(R) InCup(TM) and Rapid TOX(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(TM) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2004, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Aug 1, 2005
Previous Article:Steven Fein joins Mercer Human Resource Consulting as Global Leader of Technology.
Next Article:Recruiternet's Projectix Solution Wins HR Systems Excellence Award.

Related Articles
American Bio Medica Reports Fiscal Year End 2004 Results.
American Bio Medica Supplying Mexican Army with Drug Testing Products.
American Bio Medica Announces First Quarter 2005 Results.
American Bio Medica Launches New Rapid TOX Product; Company to Exhibit Product at 2005 American Association of Clinical Chemistry Annual Meeting &...
ABMC Reports Second Quarter Results; Sales Increase 13.2% from Prior Year Quarter.
ABMC Reports Third Quarter Results.
American Bio Medica Reports Fiscal Year End 2005 Results.
American Bio Medica Announces First Quarter 2006 Results.
American Bio Medica Announces Second Quarter 2006 Results.
ABMC Granted U.S. Patent for Lateral Flow Immunoassay Device; Covers Expanding Saliva Diagnostics Product Line.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters